| Urinary diversion and bladder reconstruction/replacement using intestinal segments for intractable incontinence or following cystectomy JD Cody, G Nabi, N Dublin, S McClinton, DE Neal, R Pickard, SM Yong Cochrane Database of Systematic Reviews, 2012 | 195 | 2012 |
| Laparoscopic in situ ablation of liver cancer with cryotherapy and radiofrequency ablation IS Tait, SM Yong, SA Cuschieri Journal of British Surgery 89 (12), 1613-1619, 2002 | 92 | 2002 |
| Is orthotopic bladder replacement the new gold standard? Evidence from a systematic review G Nabi, SM Yong, E Ong, G McPherson, A Grant, J N’DOW The Journal of urology 174 (1), 21-28, 2005 | 62 | 2005 |
| A matching‐adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia AS Kittai, A Skarbnik, M Miranda, ASM Yong, J Roos, R Hettle, ... American Journal of Hematology 98 (12), E387-E390, 2023 | 9 | 2023 |
| Real‐world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the UK P Hillmen, J Xie, ASM Yong, C Waweru, TA Sorof, RK Goyal, KL Davis EJHaem 2 (2), 219-227, 2021 | 9 | 2021 |
| A MATCHING‐ADJUSTED INDIRECT COMPARISON OF THE EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS ZANUBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA. P Ghia, A Skarbnik, M Miranda, AS Yong, J Roos, R Hettle, ... Hematological Oncology 41, 2023 | 4 | 2023 |
| A matching-adjusted indirect comparison (MAIC) of the efficacy and safety of acalabrutinib (acala) versus zanubrutinib (zanu) in relapsed or refractory chronic lymphocytic … A Kittai, A Skarbnik, M Miranda, ASM Yong, J Roos, R Hettle, ... Journal of Clinical Oncology 41 (16_suppl), 7540-7540, 2023 | 3 | 2023 |
| A Matching-Adjusted Indirect Comparison of Acalabrutinib with and without Obinutuzumab Versus Zanubrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia JN Allan, AS Kittai, D James, H Ridge, M Miranda, A Yong, F Fam, J Roos, ... Blood 142, 6563, 2023 | 1 | 2023 |
| P642: A MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS ZANUBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA A Skarbnik, A Kittai, M Miranda, A Yong, J Roos, R Hettle, ... HemaSphere 7 (S3), e4236347, 2023 | 1 | 2023 |
| Real-world treatment patterns and adverse events in patients with Chronic Lymphocytic Leukemia treated with Ibrutinib in the UK: a preliminary analysis J Xie, A Yong, C Waweru, TA Sorof, RK Goyal, KL Davis, G Follows, ... Blood 134, 5885, 2019 | 1 | 2019 |
| 90: A Systematic Review of Urinary Tract Infections Following Transposition of Bowel Segments into Urinary Tract N Ghulam, SM Yong, E Ong, A Grant, GC McPherson, JMO N’Dow The Journal of Urology 171 (4S), 24-24, 2004 | 1 | 2004 |
| An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL AS Kittai, JN Allan, D James, H Bridge, M Miranda, ASM Yong, F Fam, ... Blood Advances 8 (11), 2861-2869, 2024 | | 2024 |
| 156: Systematic Review of Surgery for Urinary Diversion, Bladder Reconstruction or Replacement: Quality Assessment of Literature SM Yong, G Nabi, E Ong, GC McPherson, A Grant, JMO N'Dow The Journal of Urology 171 (4S), 41-41, 2004 | | 2004 |
| 977: Membrane Bound Mucins MUC1, MUC4 and MUC16/CA-125 are Preferentially Expressed in Muscle Invasive Bladder Cancer SM Yong, KN Stewart, AM Pollock, A Babalgith, E Pavlidou, A Alhasso, ... The Journal of Urology 171 (4S), 259-259, 2004 | | 2004 |
| Membrane-bound mucin expression in bladder cancer. SM Yong, KN Stewart, AO Babalghith, KN Grigor, E Pavlidou, SD Heys, ... European Journal of Surgical Oncology 30, 1027-1028, 2004 | | 2004 |
| Mucin gene expression in superficial bladder cancer: identifying novel mucin tumour markers SM Yong, KN Stewart, AM Pollock, J N'Dow, AC Schofield British Journal of Cancer 88 (Suppl. 1), S46, 2003 | | 2003 |
| MUC1 and MUC16/CA125 expression in superficial bladder cancer and normal urothelium. SM Yong, KN Stewart, AM Pollock, JMO N'Dow, AC Schofield European Journal of Surgical Oncology 29, 787-787, 2003 | | 2003 |
| Mucin expression in normal urothelium and superficial bladder cancer. SM Yong, KN Stewart, AM Pollock, JMO N'Dow, AC Schofield Scottish Medical Journal 48, 130-130, 2003 | | 2003 |
| MUC1, MUC2, MUC5AC expression in superficial bladder cancer. SM Yong, KN Stewart, AM Pollock, A Alhasso, AC Schofield, JMO N'Dow BJU International 91, 60-61, 2003 | | 2003 |
| Laparoscopic in situ ablation (ISA) of liver cancer with cryotherapy and/or radiofrequency IS Tait, SM Yong, A Cuschieri BRITISH JOURNAL OF SURGERY 89, 88-88, 2002 | | 2002 |
Alan SkarbnikDirector, Lymphoma and CLL Program , Novant Health Cancer Institute在 novanthealth.org 的电子邮件经过验证
